Infectious Diseases

COVID-19 has raised the importance of research into fighting infectious diseases that threaten populations.

COVID-19 vaccines: Post-authorisation safety surveillance

This whitepaper explores the multifaceted challenges of COVID-19 post-authorisation safety surveillance studies and how business intelligence tools can benefit these efforts. 

Read the whitepaper

Assessing strategies for mitigating infectious diseases

Public health officials turn to evidence as the basis for their health policies to control the spread of infections. However, many nuanced factors can influence variations in the number of infections caused by a single infected individual.

Watch the webinar: An introduction to infectious disease modelling

In this whitepaper, we explain the basic measures used to quantify infectious disease transmission and introduce the principles of dynamic modelling to inform the selection of the most effective and cost-efficient strategies for mitigating infectious diseases.

Read the whitepaper

Fortifying vaccines: Preparation and prevention against future infectious disease epidemics

This whitepaper presents infrastructural and strategic considerations for strengthening vaccine development so that the medical community will be prepared to respond to future pandemics and novel diseases.


Read the whitepaper

Antimicrobial resistance

The World Health Organization calls antimicrobial resistance, resulting from the overuse of antibiotics or other drugs, one of the top 10 public health threats. In fact, the next global pandemic could be another novel respiratory pathogen of zoonotic origins or a multidrug resistant strain of a previously eradicated pathogen.

Watch the webinar: Antimicrobial resistance - How clinical research can combat an ensuing global crisis

In this whitepaper we provide a framework for understanding the antimicrobial crisis and the role healthcare and biopharma industries have to play in mitigating the impact of future pandemics.

Read the whitepaper

The evolution of HIV treatments

HIV is highly heterogeneous, creating barriers to diagnosing and treating the disease. Moreover, the HIV epidemic varies by region and country, necessitating different clinical research strategies across geographies. In this whitepaper, we discuss opportunities for addressing these challenges, best practices for managing infectious disease clinical trials and recent developments in HIV treatment.

Read the whitepaper

Pandemic respiratory vaccine clinical trials: A departure from business as usual

Vaccine trials for respiratory viruses, even in the best of circumstances, present a number of operational challenges for researchers, many of which are exacerbated in the face of a pandemic created by a novel virus. We focus on the corresponding success factors that can keep pandemic respiratory vaccine trials running at optimal speed and efficiency. 

Read the whitepaper

HIV infographic

HIV treatments: What has been achieved?

Before antiretroviral treatment availability, life expectancy for a person living with HIV was reduced by approximately 12.5 years. Now, this same individual will have near-normal life expectancy.

Download the infographic

Infectious diseases and vaccines media contributions

Receive more insights on infectious diseases and vaccines from ICON

Please visit ICON's Preference Centre and select 'Infectious Diseases and Vaccines' under 'Therapeutic Areas of Interest' to receive new insights on infectious diseases and vaccines.

Receive new insights

Infectious diseases and vaccines services

ICON’s extensive Infectious Disease expertise enables us to consistently select the best sites, expedite start-up timelines, and achieve enrolment targets for our clients. We apply proven strategies to clinical trials that minimise risk and generate high-quality, reliable data reducing the time and cost of bringing new therapies to market.

Read more about ICON's services in infectious diseases and vaccines